High user satisfaction rates with DEXCOM™; continuous glucose monitoring device in people with type 1 diabetes - a pilot cross-sectional study

Benai Paponette; Laura Keaver; Peter Lynch; Elias Eltoum; Liam Clarke; Jordan Carty; Siobhan Bacon; Catherine McHugh

doi:10.1530/endoabs.115.EP13

EP13

Prev Next

Section Contents Cite

Endocrine Abstracts (2026) 115 EP13 | DOI: 10.1530/endoabs.115.EP13

IES2025 Research, Audit and Quality Improvement Projects E-Posters (60 abstracts)

High user satisfaction rates with DEXCOM™ continuous glucose monitoring device in people with type 1 diabetes – a pilot cross-sectional study

Benái Paponette ¹ , Laura Keaver ² , Peter Lynch ² , Elias Eltoum ¹ , Liam Clarke ² , Jordan Carty ² , Siobhan Bacon ¹ & Catherine McHugh ^1,

Author affiliations

¹Sligo University Hospital, Sligo, Ireland; ²Atlantic Technological University, Sligo, Ireland

DEXCOM™ continuous glucose monitoring devices (DCGM) have been shown to improve glycaemic control and complication rates in people with Type 1 diabetes (T1DM). This study aimed to assess DCGM users satisfaction rates and experiences with device features in patients with T1DM in Ireland. A questionnaire consisting of open and closed ended questions together with a glucose monitoring satisfaction survey (GMSS) was offered to all patients attending Sligo University Hospital diabetes clinic who used a DCGM for at least six months. Data was analysed on 73 participants. Self-reported QOL improved in 88% of participants and 52% of participants reported fewer hypoglycaemic events. The features most liked by participants were alerts given when glycaemic target was not in range, improved quality of life, improved hypoglycaemia awareness and the need for reduced finger pricking. Concerns were also identified about redundant alarms and sensor failures, phone incompatibility and skin reactions. DCGM was associated with good levels of glucose monitoring satisfaction with an overall satisfaction score of 3.67±1.24 out of 5. Participants reported high openness (4.01 ±0.91), increased trust (3.77±1.16) and low emotional (1.70 ±0.97) and behavioural burden (2.38 ±1.10) with DCGM usage. Male participants who had diabetes for a mean duration of 20.06 ± 0.89 years and used DEXCOM™ for approximately 2 years demonstrated significantly higher levels of satisfaction (P < 0.05). The findings of this study provide first exploration of patients’ perspectives on DCGM devices in an Irish setting. Results suggest that DCGM users are highly satisfied with the device with increased self-reported QOL.